Conference Recap: Fall Clinical 2024

To stay informed with the latest conference insights, subscribe to receive our eNewsletters.

Previewing the 2024 Fall Clinical Dermatology Conference: What to Expect

The conference aimed at providing dermatology clinicians with the latest in the specialty begins today in Las Vegas, Nevada.

POLL: What Topics Are You Looking Forward to at Fall Clinical 2024?

Share with us the topics you want to learn more about at Fall Clinical.

Gearing Up for Fall Clinical 2024 With Raj Chovatiya, MD, PhD

The conference will feature presentations on a number of disease states, therapeutic options, and new clinical data.

Previewing Editorial Advisory Board Member Sessions at Fall Clinical 2024

Among the many sessions to be held at the Fall Clinical Dermatology Conference in Las Vegas, Nevada, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.

The Latest in Dermatology With James Del Rosso, DO: Part 1

Del Rosso reviews numerous new and upcoming topical therapeutics and indications including ruxolitinib, tapinarof, and more.

'Stop Writing Systemic Corticosteroids for Atopic Dermatitis': Expanding the Toolkit for AD

Clinicians presented a panel-style session at Fall Clinical, touching on the drawbacks of topical steroid use and alternatives in AD patients.

New LEVEL UP Period 2 Data Shows Patients Who Switched From Dupilumab to Upadacitinib Achieved Higher Treatment Targets in AD

Christopher Bunick, MD, PhD, presented the latest period 2 data at Fall Clinical 2024.

Guselkumab Demonstrates Significant Skin Clearance in Hard-to-Treat Moderate Psoriasis Sites

Phase 3b study showed promise in clearing moderate PsO in sensitive areas for patients unresponsive to topical treatments.

The Latest in Dermatology With James Del Rosso, DO: Part 2

Del Rosso reviews available and upcoming monoclonal antibodies, including nemolizumab, lebrikizumab, bimekizumab, and more.

Game-Changing Insights on Itch, Psoriatic Disease, and Innovations With Mona Shahriari, MD, FAAD

Shahriari highlighted advanced dermatology treatments, clinical trial inclusivity, and key care strategies for complex skin conditions at Fall Clinical 2024.

Available Therapeutics and Upcoming Advancements in Atopic Dermatitis and Prurigo Nodularis

Shawn Kwatra, MD, reviews key highlights of his sessions at Fall Clinical 2024 on the latest updates in itch conditions.

Long-Term Results Demonstrate Clinically Meaningful Improvements in Hair Regrowth Following Oral Deuruxolitinib

Sun Pharma presented long-term data on Leqselvi 8 mg tablets, showing significant scalp hair regrowth in severe alopecia areata patients.

Final ECZTEND Study Results Confirm Long-Term Safety and Efficacy of Tralokinumab for Moderate-to-Severe Atopic Dermatitis

Adbry achieved EASI-75 in 92.9% and IGA 0/1 in 66.7% of AD patients, with a strong safety profile.

Exploring Advancements in Palmoplantar Pustulosis, Psoriasis Comorbidities, and Phototherapy

Joel Gelfand, MD, discusses insights on complex psoriasis cases, comorbidity management, and the evolving role of phototherapy at Fall Clinical 2024.

Lebrikizumab Demonstrates Efficacy in Itch and Skin Clearance Among Patients With AD Who Discontinued Dupilumab

The phase 3b study shows Ebglyss reduced eczema severity and itch in challenging areas, with 60% of prior dupilumab patients meeting key improvement by week 24.

Innovative Insights in Skin Cancer Prognosis, Gene Expression Profiling, and Early Career Tips

Aaron Farberg, MD, explores advancements in melanoma and cSCC prognostic tools, the role of gene expression profiling in inflammatory diseases, and initiatives aimed at supporting early-career dermatologists at Fall Clinical 2024.

Raj Chovatiya, MD, PhD: Current Disease States and Early Career Controversies

During an interview with Dermatology Times, Chovatiya outlined his Fall Clinical 2024 presentations on chronic and eczema and early career controversies.

Rocatinlimab Improves SCORAD in Adults With Moderate to Severe AD

A poster presentation from Fall Clinical 2024 detailed the effect of rocatinlimab on SCORAD scores across baseline characteristic subgroups in adults with moderate to severe atopic dermatitis.

Study Reveals Comparable Efficacy of Clascoterone, Trifarotene, and Tazarotene in Acne Treatment

The recent meta-analysis revealed comparable efficacy in treating acne vulgaris and was presented at Fall Clinical 2024.

James Song, MD, FAAD: Advanced Strategies for Alopecia Areata, Refractory Dermatoses, and Emerging Non-Steroidal Topicals

Song shared top clinical tips at Fall Clinical, covering alopecia areata, refractory dermatoses, and novel non-steroidal topicals.

Emmy Graber, MB, MBA, Shares Top Clinical Pearls on Lasers, Erythema Treatments, and Emerging Therapies

At Fall Clinical 2024, Graber spotlighted precise acne-targeting lasers, new combination creams, and a promising rosacea pill awaiting FDA approval.

Elevating Standards in Atopic Dermatitis Through JAK Inhibitors and Optimal Treatment Targets

At Fall Clinical 2024, Christopher Bunick, MD, PhD, discussed systemic therapy options and the importance of comprehensive treatment targets in managing atopic dermatitis, emphasizing AHEAD recommendations and LEVEL UP data.

Glynis Ablon, MD, Spotlights Top Devices and Innovations in Aesthetic Dermatology

At Fall Clinical 2024, Ablon shared her top device-based interventions, from wound care to radiofrequency rejuvenation, revealing clinical pearls for enhanced aesthetic outcomes.

Deucravacitinib Shows Significant Efficacy and Safety in Phase 3b/4 Trial for Moderate to Severe Scalp Psoriasis

Deucravacitinib demonstrated significant efficacy and safety in treating moderate to severe scalp psoriasis, as shown in the PSORIATYK SCALP trial presented at Fall Clinical.

High Stakes in Dermatology: Jackpot Insights from Fall Clinical 2024

Discover top innovations, insights, and clinical pearls from Fall Clinical in Las Vegas, where dermatology’s biggest breakthroughs took center stage.

Day 4 Recap: Fall Clinical 2024

Catch up on coverage from the final day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

Uncovering Systemic Corticosteroid Use and Updates on Long-Term Management Benefits of Upadacitinib in AD

At Fall Clinical 2024, Christopher Bunick, MD, PhD, presented findings on the prevalence of systemic corticosteroid use among patients with atopic dermatitis and highlighted how those treated with upadacitinib achieved and sustained optimal skin clearance and itch relief long-term.

To view all conference coverage from Fall Clinical 2024, click here.